

Commercializing Genetic Testing for the Early Detection of Diseases

September 2017



CNA Diagnostics Inc.

Disclaimer

This Presentation is based upon information supplied by CNA Diagnostics Inc. ("CNAD" or the "Company") solely for use by prospective strategic partners and/or investors in the company. This Presentation does not purport to be all-inclusive or to contain all of the information that a prospective strategic partner and/or investor may desire. No representation or warranty is made as to the accuracy or completeness of any of the information contained herein. Each recipient of this memorandum agrees that all of the information contained herein is of a confidential nature, that he will treat it in a confidential manner, and that he will not directly or indirectly, disclose, or permit his agents or affiliates to disclose, any of such information without the prior written consent of the Company. Neither this Presentation, nor its delivery to any prospective strategic partner and/or investor, shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall this Presentation be construed to indicate that there has been no change in the affairs of the Company. This Presentation contains "forward-looking information", which is disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action. In particular, the forward-looking information in this presentation includes: statements regarding timing and outcomes of


research, development, and commercialization activities, financing activities, protection of intellectual property, market share and growth. Actual results may vary from the forward-looking information in this presentation. Material risk factors that could cause actual results to differ materially from the forward-looking information include: (i) CNAD's ability to develop commercially viable products; (ii) CNAD's ability to achieve profitability; (iii) CNAD's ability to produce and market its products; (iv) CNAD's ability to obtain regulatory approval of its products; (v) CNAD's ability to protect its intellectual property; (vi) competitive and alternative technologies; and (vii) CNAD's ability to obtain financing to support its operations. The material factors or assumptions that were used to develop the forward-looking information in this presentation include: our ability to achieve research and development objectives, timing of proposed commercialization plans, ability to protect intellectual property, ability to secure needed financing or our ability to develop sufficient margins in the business through development of proposed technology or other means. CNAD's views regarding possible events, conditions or financial performance may change. However, CNAD does not intend to update the forward-looking information in this presentation, except as required by applicable securities legislation.



Company Overview

- CNA Diagnostics Inc. (CNAD) is a Molecular Diagnostics company that develops tests for a wide spectrum of human and animal diseases long before the presence of the first clinical signs.

“An ounce of prevention is worth a pound of cure.”



At a Glance

- Proprietary technology that identifies chronic diseases at early stages.
- Building a portfolio of commercial tests to diagnose highest impact diseases: bovine, porcine, equine, canine, feline, and human.
- Pending distribution through license agreements with well-known major industry participants for 67 countries.
- High barriers to entry, seasoned leadership, proven science.
- \$1M investment all inclusive per test with each test having significant commercial potential.
- Raising \$2.0 – \$5.0M Q4 2017.

First Commercial Test: Johne's Disease

- Bacterial infection of the intestine.
- 250M dairy cattle worldwide.
- 68% of herds in US infected (approx. 6.3M cattle).
- Lost productivity estimated at \$250M annually in US.
- Clinical signs only appear very late if at all.
- Slow progressive wasting of animal.
- Solution is to cull the animal.
- Current blood and stool tests are only 30-60% (+/- 5%) effective.
- Current test takes days to weeks for results.
- Market is seeking a solution (production losses, export problems, animal breeding issues).



CNA Diagnostics Inc.

CNAD Johne's Test


- Affordable prototype test available Q4 2017.
- >90% sensitivity and specificity expected.
- Same day results.
- Animals removed from herd – stops the spread of the disease.
 - Increased productivity.
- Addressable market 250M cattle.
- Leveraging Canadian and International partnerships to enter market.
- Johne's testing has been specifically chosen by CNAD for its immediate commercial value.

Johne's Competition

Test	Test Provider	Advantages	Disadvantages	Time	Cost	Sensitivity
Fecal Culture	Animal Health Labs	Detects fecal shedding	False negatives Sample collection	1-12 weeks	~\$30 per sample plus collection	30-60%
Serum ELISA	Animal Health Labs	Cost efficient	False negatives Sample collection	5-7 days	~\$8 per sample plus collection	30-60%
Milk ELISA	CanWest DHI	Cost efficient Easy and convenient sample	False negatives	2-3 days	\$9 per sample plus handling	30-60%
Gene Expression	Genethera	Better sensitivity than protein tests	Very fragile RNA is used, not really useful for field testing	Several hours	>\$100 Estimated	>90% Estimated
CNA BioMarkers	CNA	Stable DNA used, easy to administer test Reliable results.	Positioned to be more expensive than current tests	2-3 hours	TBD	>90%


Building a Diagnostic Disease Portfolio

Locking in the Top Five Economically Significant Diseases for Each



Market Opportunity


Estimated Worldwide Populations




CNAD is currently working with partners in each industry.




Circulating Nucleic Acids (CNA)



Body responds to challenges as it fights to return to normal.



Cells die as part of normal life (Apoptosis). DNA information regarding cell activity is released into the blood and protected in a double membraned vesicle.



Informative molecules packaged in vesicles enter into cells in another tissue and cause a reaction by the cells of this tissue.

Identification of Biomarkers



Time series samples from diseased mammals are collected and sequenced with high-throughput methods (billions of reads per experiment).



Proprietary mathematical and computational codes compare diseased segments to the normal mapped mammal genome.



Biomarkers only present or absent in the diseased state are identified and patented.
 $\alpha < 0.0001$

***7 years to develop proprietary technology –
CNAD owns 100% and patents biomarkers for each disease.***

In the Field



Blood sample collected.



Sample is prepared and run through a standard RT-PCR machine. In 2-3 hours CNAD identifies if disease state / biomarkers are present.



Effective early stage treatments can be considered before signs of disease appear.

Proof of Concept & Building an IP Portfolio

Mammal	Challenge	Identification	Value	Commercial Use
Rats	Radiation	Identify impact within 1 hour	Proof of concept	None yet
Elk	Chronic wasting	10 months before clinical signs	Proof of concept	None
Beef Cattle	Bovine Spongiform Encephalopathy	10 months before clinical signs	Prevents transfer to humans and other animals	Government not supportive
Human*	Bacterial Sepsis/ Candida Sepsis	3 days before clinical signs	Saves lives 50% death rate 1 million infections in USA each year	Wide spread, plans for patient monitoring being developed with MedUni Graz
Bovine	Johne's Disease	TBD in Q3 2017	Increased production	Significant
Bovine	Bovine Respiratory Disease	TBD in Q4 2017	Increased production, reduced death rate 10% death rate	Significant

* Human studies are currently conducted at full cost recovery only as the lengthy time to market increases the business risk. CNAD is focused on solutions that can be quickly commercialized.



CNA Diagnostics Inc.

Go to Market Plan

- CNAD is a molecular diagnostics company with an expanding IP biomarker portfolio, which will be monetized through the sale of testing distribution rights.
 - Alpha field tests for Johnes and Bovine Respiratory Disease planned beginning Q4 2017, followed by full product roll out.
- Multiple Partnerships provide in depth access to samples.
- Strategic partnerships (pending) with distributors in specific verticals and regions.
 - European distributor for 67 countries (Europe, Russia, North Africa, Middle East) re. bovine and porcine diseases.
 - Feedlot Health Management Services – Canada.
 - Developing partnership with companion animal hospital operator in USA for canine and feline diseases.
 - Chinese distributor for bovine and porcine expected in coming months.
- Full Cost Recovery Research Projects
 - Department of National Defense Contract for Human Sepsis (full cost recovery only).
- Partnerships with suppliers established.
 - PCR machines and testing equipment.

Diagnostic Test Portfolio Development

Current	Q2/17	Q3/17	Q4/17	Q1/18	Q2/18	Q3/18	Q4/18
Phase 1 – Active							
Johne's Disease – Bovine	Marker ID	IP	Field Test	Early sales			
BRD – Bovine	Sequencing	Marker ID	IP	Field Test / Early Sales	Early sales		
Sepsis Bacterial (Phase 2) – Human	New Samples	Sequencing	Sequencing	Marker ID	Field test	IP	
Phase 2 – Identified							
Anemia (Companion Animals)		Samples	Sequencing	Marker ID	IP & Field Test	Early Sales	
Porcine Disease 1		Samples	Sequencing	Marker ID	IP & Field Test	Early Sales	
Phase 3 – Partner tests							
Bovine Disease 3			Samples	Sequencing	Marker ID	IP & Field Test	Early Sales
Porcine Disease 2				Samples	Sequencing	Marker ID	IP & Field Test
Equine Disease 1				Samples	Sequencing	Marker ID	IP & Field Test
Commercially Available Tests	0	0	0	1	2	4	5

Each diagnostic test costs approximately \$1M to develop. Additional capital can be deployed to accelerate the test pipeline. Each test addresses a substantial market. Competitors usually focused on only one test.



Management



David L. Gordon CEO, CFO

David is a business and financial professional with +15 years' experience optimizing business performance and effectively deploying capital to maximize an organization's potential. David has developed and lead high functioning teams, solved complex financial and cultural based organizational problems and is experienced in the unique challenges facing small and quickly growing entities.

David has previously held positions as an Investment Analyst with AIC Ltd, as a Management Consultant with Western Management Consultants, as an Investment Banking Associate with CIBC, and as the Leader of Strategy and Performance for a large public organization. David has worked on investor campaigns for Reservlogix, Neptune Technologies and Biorresources and many other technology driven organizations. He holds a Chartered Financial Analyst (CFA) designation; is a Project Management Professional (PMP); won the silver medal in Operations Management for his Commerce degree; has completed the CPA CFO operational skills course; is well versed in leadership strategy and has published articles on strategy execution.



Dr. Christoph W. Sensen CSO

A founding member of CNA Diagnostics Inc., Dr. Sensen is a University Professor for Computational Biotechnology at the Graz University of Technology in Austria and an Adjunct Professor at the University of Calgary's Faculty of Medicine, Department of Biochemistry and Molecular Biology. He participated in several large-scale Genome Research programs, including two for the development of markers for CWD and BSE, and co-Author on more than 100 peer-reviewed articles and has edited or published six books in the field of Genome Research and Bioinformatics. Dr. Sensen is a reviewer for granting agencies and Journals; and Chief Editor at Journal of Biotechnology (Elsevier).

Previously he worked for seven years as a Research Officer at the National Research Council of Canada's Institute for Marine Biosciences (NRC-IMB) and as a visiting scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg (13 months). He studied Biology in Mainz, Düsseldorf and Cologne and obtained a Dr. rer. nat. degree from the University of Cologne in 1994.



Independent Board and Advisors



Dr. Greg Andrews
Chairman, Director



Dr. G. Kee Jim
Director



Dennis L. Nerland, QC
Director



Alec Milne
Director



Dr. David Chalack
Scientific Advisor



Dr. Robert B. Church
Scientific Advisor

CNA Diagnostics Inc.

Recent Industry Consolidation

- GH0 Capital acquires DNA Diagnostics for €104 million / \$152 million CAD.
 - DNA profiling company testing animals for potential disease candidates.
- Merck buys 93% of Brazil animal health company Vallée for \$400 million.
- Boehringer Ingelheim buys Merial Animal Health, a division of Sanofi for €11.4 bn / \$16.7 bn CAD.
- Mars Inc. agrees to buy the animal hospital chain VCA Inc. for \$7.7 billion making a bigger bet on a booming industry: pet care.
- Grail raises \$900M for liquid biopsy cancer screening.

15.0M Common Shares
0.5M Options
2.4M Warrants

17.9M Fully Diluted

Highlights

- Proprietary technology that identifies chronic diseases at early stages.
- Building a portfolio of commercial tests to diagnose highest impact diseases: bovine, porcine, equine, canine, feline and human.
- Pending distribution through license agreements with well-known major industry participants for 67 countries.
- High barriers to entry, seasoned leadership, proven science.
- \$1M investment all inclusive per test with each test having significant commercial potential.

Proof of Principle

- International Immunology, 2005: Exosomal-like vesicles are present in human blood plasma – Marie-Pierre Caby, Danielle Lankar, Claude Vincendeau-Scherrer, Graca Raposo and Christian Bonnerot
- Nucleic Acid Research 37:550-556 – 2009: Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with TSE's. – Paul Gordon, Ekkekard Schultz, Robert B. Church and Christoph Sensen
- Mitra et al., 2015: Journal Bioscience 40: 91-111 – Exosomes are taken up by mouse cells, their DNA enters the nucleus and is integrated into the mouse genome within minutes, all cells “transformed” within 30 minutes with 100% efficiency.
- DRDC Suffield; 2011 – 2015: Identification of Radiation Markers in Rats; Identifying CNA Biomarkers in Sepsis – U of C – Christoph Sensen
- ALMA - 2008 to 2012: Identification of Disease Specific motifs for CWD in elk and BSE in live cattle – U of C – Christoph Sensen

Jeff Walker
Investor Communications
+1 403.221.0915
jeff@howardgroupinc.com

David Gordon, CEO/CFO
+1 403.465.0241
david@CNADiagnostics.com

Dr. Christoph Sensen, CSO
+43 664.438.3684
christoph@CNADiagnostics.com



CNA Diagnostics Inc.

Suite 300
5 Richard Way SW
Calgary, Alberta
T3E 7M8

+1 403.910.1834

www.CNADiagnostics.com